Research Papers:

MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells

Ziv Versano, Eitan Shany, Shany Freedman, Liron Tuval-Kochen, Moshe Leitner, Shoshana Paglin, Amos Toren and Michal Yalon _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:27547-27563. https://doi.org/10.18632/oncotarget.25547

Metrics: PDF 1299 views  |   HTML 1864 views  |   ?  


Ziv Versano1,2,*, Eitan Shany1, Shany Freedman1,2, Liron Tuval-Kochen1,2, Moshe Leitner1, Shoshana Paglin1,**, Amos Toren1,2,** and Michal Yalon1,3,**

1Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan 52621, Israel

2Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

3The Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan 52621, Israel

*The work was performed in partial fulfillment of the requirements for the Ph.D. degree of Ziv Versano, Sackler School of Medicine, Tel Aviv University

**These authors have contributed equally to this work

Correspondence to:

Michal Yalon, email: [email protected]

Keyword: MutT homolog 1; Nudix hydrolase; adult and pediatric glioblastoma; histone deacetyase inhibitors; PARP-1 inhibitors

Received: November 16, 2017    Accepted: May 19, 2018    Published: June 08, 2018


Glioblastoma, a fatal disease in both adult and pediatric patients, currently has limited treatment options that offer no more than temporary relief. Our experiments with adult and pediatric glioblastoma cell lines showed that radiation induces a dose-dependent increase in the level of MutT homolog 1 (MTH1) - an enzyme that hydrolyzes oxidized purine nucleoside triphosphates. Similarly, the combination of vorinostat, which is a histone deacetylase inhibitor, and ABT-888, which is a PARP-1 inhibitor, enhanced clonogenic death and increased the MTH1 level, relative to each treatment alone. This result suggests that the MTH1 level is directly related to the damage that is inflicted upon the cells, and its activity protects them against anti-neoplastic therapy. Indeed, the MTH1 inhibitor TH588 and MTH1 siRNA increased glioblastoma’s response to both radiation and the combination of vorinostat and ABT-888. TH588 also inhibited glioblastoma’s capacity for migration and invasion. In normal fibroblasts, low radiation doses and the combination of vorinostat and ABT-888 decreased the level of the enzyme. TH588 did not alter the fibroblasts’ response to radiation and only mildly affected their response to the combination of vorinostat and ABT-888.

In summary, the inhibition of MTH1 is required to better realize the therapeutic potential of anti-neoplastic treatments in glioblastoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25547